Key Record Dates
| ClinicalTrials.gov Identifier: | NCT05232071 |
|---|---|
| Brief Title: | Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus (LEGEND) |
| First Submitted : | January 26, 2022 |
| First Submitted that Met QC Criteria : | February 8, 2022 |
| First Posted : | February 9, 2022 |
| Last Update Submitted that Met QC Criteria : | February 22, 2024 |
| Last Update Posted : | February 23, 2024 |